The median age at first diagnosis is 60 years and the male-to-female ratio is almost even (1:1.4). Typically, CML develops in three phases. The vast majority of patients (>80%) is diagnosed in the initial chronic phase, which-in the absence of any treatment-lasts for approximately 3-6 years, before patients enter into the advanced and often terminal stages of the disease, called the accelerated phase and/or blast crisis, respectively. 2 Typical hematological features of chronic-phase CML are an increase of total leukocyte count, expansion of myeloid progenitor cells in the peripheral blood and bone marrow, thrombocytosis, and splenomegaly. Progression of CML into accelerated phase can be defined as any of the following: blast cells in blood or bone marrow between 15 and 29%; blast cells plus promyelocytes in the peripheral blood or bone marrow above 30% with less than 30% blasts; basophils in the peripheral blood above 20%; or persistent thrombocytopenia. 3 Blast crisis CML, commonly associated with a median survival of less than six months, is marked by more than 30% myeloblasts in either bone marrow or blood.
The pivotal genetic abnormality of CML is a reciprocal, balanced chromosomal t(9;22)(q34;q11) translocation also known as the Philadelphia chromosome, which is restricted to the malignant clone and which can be detected cytogenetically or by fluorescent in situ hybridization (FISH) analysis in more than 90% of all patients with CML. 4 This chromosomal alteration fuses the Abelson (ABL) tyrosine kinase gene, originally located on chromosome 9, with the breakpoint cluster region (BCR) gene, originally located on chromosome 22, resulting in the BCR-ABL oncogene. 5, 6 In CML patients the BCR-ABL oncogene generates the p210 BCR-ABL tyrosine kinase that activates specific pathways, resulting in the leukemic phenotype.
In summary, CML is defined as a monoclonal, hematopoietic stem cell disorder, caused by the constitutively activated, highly oncogenic p210 BCR-ABL kinase.
Imatinib Mesylate
The concept of targeted therapy as a treatment modality of malignant diseases is based on small molecules-kinase inhibitors-aiming at cancer-specific target structures of the malignant cell.
Unprecedented therapeutic success was observed when imatinib (Glivec/Gleevec, Novartis Pharma AG), a 2-phenylaminopyrimidine derivative with a low molecular weight of 589.7kD, was designed and developed. 7, 8 Imatinib is acting as a competitive inhibitor of adenosinetriphosphate (ATP)-dependent phosphorylation of BCR-ABL, freezing the oncoprotein in the inactive and closed conformation, thereby resulting in BCR-ABL dephosphorylation and inactivation. [8] [9] [10] The specific structure of the ABL catalytic domain, which is incorporated in BCR-ABL, shows a bilobate structure with a smaller N-terminal and a larger C-terminal lobe.
The cleft separating these two lobes contains-among other amino acids The most recent phase II data are derived from a multicenter, international trial in over 100 centers with nearly 800 patients. 19 Patients enrolled into this trial were suffering from either Ph+ CML or ALL, or were diagnosed for hypereosinophilic syndrome or systemic mastocytosis. CML or ALL patients could be enrolled because of either previous imatinib resistance or imatinib intolerance.
Most importantly, more than 45 point mutations have been identified that interfere with a proper binding of imatinib in the binding domain.
Leukemias & Lymphomas
In the chronic-phase population, imatinib resistance was defined as not having achieved a CHR after at least three months of therapy, no minimal cytogenetic remission after at least six months, or no major cytogenetic remission (MCyR) after at least 12 months of therapy. Alternatively, patients could be enrolled because of secondary resistance, defined as the loss of a previously achieved CHR or MCyR. All resistant patients had to be pre-treated with at least 600mg/day imatinib for three months. In contrast, the definition of imatinib intolerance is, naturally, less stringent.
In this study the definition of imatinib intolerance required that imatinib was discontinued and that patients did not have a baseline MCyR.
Baseline characteristics of the chronic-phase patients who were evaluated for toxicity (n=318) showed 70.1% imatinib-resistant versus 29.9%
imatinib-intolerant patients. The median exposure to nilotinib was 245 days (range 1-502) and the median dose intensity of 796.6mg/day was only insignificantly below the intended dose of 800 mg/day, and is indicative for a relatively good tolerability. Importantly, the chronic-phase study population of this trial included patients with a median age of 58 years (range 21-85) and relatively long disease durations of 57.3 months (range 4.9-275). Therefore, the chronic-phase population of this trial already included intensely pre-treated patients who in a substantial proportion were, aside from imatinib, pre-treated with hydroxyurea, interferon-alpha, busulfan, and systemic chemotherapy.
Efficacy was determined in the first consecutively enrolled 280 patients with at least a six-month follow-up. When only patients without a baseline CHR were considered, the rate of CHR was 74.1%. The MCyR rate in all patients at the same time was 51.8%, without any significant difference in patients who were enrolled because of resistance (50.5%) or intolerance (54.7%).
In this relatively short observation time, a median time to progression could not be determined. However, the compound is associated with both a short median time to CHR of one month (range 0.9-8. In none of the patients was any significant-above grade II-fluid retention observed.
In contrast, myelosuppression occurred in a considerable number of patients, reflecting also the therapeutic potential of nilotinib. When all grades of myelotoxicity were considered, anemia occurred in 48.6%, neutropenia in 49.7%, and thrombocytopenia in 57.3% of all cases. But severe (grade III and IV) grades of myelotoxicity occurred in only 7.9%
(anemia) to 28.4% (neutropenia and/or thrombocytopenia) with a relatively short median duration of less than 22 days. Most importantly, nilotinib shows a negligible degree of cross-intolerance towards imatinib. In 117 patients with either chronic-phase or accelerated-phase CML in this study, cross-intolerance was observed in only one patient with gastrointestinal toxicity and one patient with liver toxicity.
In summary, nilotinib represents a promising novel therapeutic agent in the treatment of imatinib-resistant or -intolerant chronic-phase CML patients.
In contrast to other second-generation kinase inhibitors in this patient population, nilotinib maintains target specificity but widens the spectrum of sensitivity, as a large number of known BCR-ABL mutants are sensitive to this substance. ■
